查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1631496

體外診斷酶市場規模、佔有率、趨勢分析報告：按酶、疾病、技術、最終用途、地區和細分市場預測，2025-2030 年

In-vitro Diagnostics Enzymes Market Size, Share & Trends Analysis Report By Enzyme (Polymerase & Transcriptase, Proteases), By Disease (Infectious Disease, Diabetes), By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

體外診斷酵素市場的成長和趨勢

根據 Grand View Research, Inc. 的一份新報告，全球體外診斷酶市場預計到 2030 年將達到 30.5 億美元。預計 2025 年至 2030 年間，市場複合年成長率為 10.2%。準確、快速地診斷和治療臨床疾病對於最佳臨床結果至關重要。由於其顯著的生物催化特性，酶被用於多種疾病的診斷。

酵素生物感測器的發展增加了酵素在臨床診斷中的效用。儘管臨床診斷需要生物感測器，但其商業化程度以及從研究到臨床的轉化程度仍然很低。然而，隨著研發力度的加大，乳酸、膽固醇和葡萄糖生物感測器正在商業化用於診斷用途。

蛋白酶是重要的訊號蛋白，對多種病理過程至關重要，包括癌症、神經疾病、發炎和心血管疾病。預計聚合酵素和轉錄酶在預測期內將表現出最快的複合年成長率。此外，大量提供這些酶的參與企業預計將促進成長。 Kaneka Eurogentec SA、東洋紡績株式會社和Sekisui Diagnostics, LLC等主要企業生產和銷售各種聚合酵素，包括 KOD DNA 聚合酶、Taq DNA 聚合酶、Tth DNA 聚合酶和 TTx DNA 聚合酶。

2019年，感染疾病領域佔據了市場主導地位。全球新冠肺炎病例的急劇增加，推動了診斷酵素在新冠肺炎診斷上的應用率。透過即時PCR 、環介導等溫擴增 PCR（LAMP-PCR）、多重 PCR 和數位 PCR 技術進行定性和定量分子檢測以診斷感染疾病的可用性不斷提高，推動了該領域對酵素的需求。

酵素免疫組織化學 (IHC) 因其更好的對比度和方法的兼容性而在組織學中受到青睞，這使得可以使用多種染色來檢測目標成分。體外診斷（IVD）酶有多種最終用途，用於組織檢體和體液的分析。體外診斷（IVD）酶被廣泛的最終用戶使用，包括每天進行多次分析的大型實驗室和進行少量測試的小型診所。

2019年，北美成為突出的區域市場。癌症患者數量的增加以及在切片檢查樣本的組織病理學測試中採用酵素是預計推動該地區市場成長的其他一些因素。龐大的目標人口、不斷改善的醫療保健基礎設施、大量未滿足的臨床需求、日益增多的政府舉措以及不斷增加的先進診斷技術研發活動預計將推動亞太市場以最快的速度成長。

市場的主要企業正在致力於新產品的發布、收購、聯盟、夥伴關係、地理擴張等，以加強其在市場上的地位。例如，2020 年 6 月，Codexis, Inc. 與 Alphazyme LLC 達成合作協議，生產並共同銷售高保真 DNA聚合酵素、T7 RNA聚合酵素和逆轉錄酶。

體外診斷酵素市場報告重點

  • 以酵素計算，聚合酵素和轉錄酶在 2024 年佔據最大佔有率，因為它們在分子診斷檢測中已廣泛應用。
  • 根據疾病，預計感染疾病部分將在整個預測期內佔據市場主導地位。
  • 基於技術，組織學檢測部分在 2024 年佔據了最大的佔有率，這歸因於組織學檢測在癌症診斷中的效用以及各種癌症類型發病率的上升。
  • 根據最終用途，醫院和診斷實驗室在 2024 年佔據市場主導地位。由於住院人數增加和入院癌症患者數量的增加，這些機構接收大量用於組織病理學和細胞病理學的切片檢查檢體。
  • 2024 年，北美佔據了整個市場的主導地位，這得益於該地區大量新參與企業，包括 Innovative Research、Bio-Rad Laboratories, Inc.、Rockland Immunochemicals, Inc.、MyBioSource.com 和 RayBIoTech, Inc.

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章體外診斷酵素市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 體外診斷酵素市場分析工具
    • 產業分析 – 波特五力分析
    • PESTEL 分析

第 4 章體外診斷酵素市場：酵素、估計與趨勢分析

  • 2024 年及 2030 年酵素市場佔有率
  • 細分儀表板
  • 全球體外診斷酵素市場（按酵素展望）
  • 2018-2030 年市場規模、預測及趨勢分析
    • 蛋白酶
    • 聚合酵素和轉錄酶
    • 核糖核酸酶
    • 其他

第5章體外診斷酵素市場：疾病預測與趨勢分析

  • 2024 年及 2030 年疾病市場佔有率
  • 細分儀表板
  • 全球體外診斷酶市場依疾病分類展望
  • 2018-2030 年市場規模、預測及趨勢分析
    • 感染疾病
    • 糖尿病
    • 腫瘤學
    • 心臟病學
    • 腎臟科
    • 自體免疫疾病
    • 其他

第 6 章體外診斷酵素市場：按技術、估計和趨勢分析

  • 2024 年及 2030 年技術市場佔有率
  • 細分儀表板
  • 全球體外診斷酶市場技術展望
  • 2018-2030 年市場規模、預測及趨勢分析
    • 組織學檢查
    • 分子診斷
    • 臨床化學

第 7 章體外診斷酵素市場：按最終用途的估計和趨勢分析

  • 2024 年及 2030 年終端用途市場佔有率
  • 細分儀表板
  • 全球體外診斷酵素市場前景（依最終用途）
  • 2018-2030 年市場規模、預測及趨勢分析
    • 製藥和生物技術
    • 醫院和診斷實驗室
    • 學術實驗室

第 8 章體外診斷酵素市場：區域、估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018-2030 年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的近期趨勢及影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 2024 年主要企業的市場佔有率分析
    • Merck KGaA
    • Codexis, Inc
    • F. Hoffmann-La Roche Ltd
    • Amano Enzymes Inc
    • Advanced Enzymes Technologies Ltd.
    • Biocatalysts Ltd
    • Amicogen
    • Dyadic International
    • BBI Solutions
    • Affymetrix
Product Code: GVR-4-68039-246-6

In-vitro Diagnostics Enzymes Market Growth & Trends:

The global in-vitro diagnostics enzymes market size is anticipated to reach USD 3.05 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 10.2% from 2025 to 2030. Accurate and rapid diagnosis and treatment of clinical disorders are essential for optimal clinical outcomes. Owing to the noteworthy biocatalytic properties, enzymes are used in the diagnosis of a wide range of diseases.

The development of enzyme biosensors has increased the enzyme utility in clinical diagnostics. Despite the necessity in clinical diagnosis, the commercialization and translation of biosensors from research to clinics are still low. However, with an increase in R&D efforts, lactate, cholesterol, and glucose biosensors have been commercialized for diagnostic use.

Proteases are important signaling proteins that are critical to a few pathological processes, including cancer, neurological, inflammatory, and cardiovascular disorders. Polymerase and transcriptase enzymes are expected to exhibit the fastest CAGR over the forecast period. In addition, the presence of a substantial number of players that offer these enzymes is expected to enhance the growth. Key players such as Kaneka Eurogentec S.A.; Toyobo Co., Ltd.; and Sekisui Diagnostics, LLC manufacture and distribute a wide range of polymerases, including KOD DNA Polymerase, Taq DNA Polymerase, Tth DNA Polymerase, and TTx DNA Polymerase.

The infectious disease segment dominated the market in 2019. An exponential rise in the COVID-19 cases globally drives the adoption rate of diagnostic enzymes for COVID-19 diagnosis. An increase in the availability of qualitative and quantitative molecular assays based on real-time PCR, Loop-mediated Isothermal Amplification- PCR (LAMP-PCR), multiplex PCR, and digital PCR technologies for the diagnosis of infectious diseases drives the demand for enzymes in this segment.

Enzymatic immunohistochemistry (IHC) is preferred for histology owing to a better contrast ratio and the method's compatibility for use with multiple stains for the detection of target components. IVD enzymes are employed in different end-use settings for the analysis of tissue specimens and bodily fluids. A wide range of end users including large laboratories that conduct multiple analyses in a day and smaller clinics that conduct a few tests use enzymes for in-vitro diagnostics (IVD).

North America emerged as a prominent regional market in 2019. A rise in the number of cancer cases and the adoption of enzymes for histopathology of biopsy samples are some of the other factors expected to propel market growth in the region. The presence of a large target population, improvements in healthcare infrastructure, high unmet clinical needs, increase in government initiatives, and rise in R&D activities for advanced diagnostic techniques are anticipated to drive the Asia Pacific market with the fastest growth rate.

The key players in the market are involved in novel product launches, acquisitions, collaborations, partnerships, and geographical expansions to reinforce their market presence. For instance, in June 2020, Codexis, Inc. signed a collaboration agreement with Alphazyme LLC for the manufacture and co-marketing of high-fidelity DNA polymerase, T7 RNA polymerase, and reverse transcriptase.

In-vitro Diagnostics Enzymes Market Report Highlights:

  • By enzyme type, polymerase and transcriptase enzymes held the largest share in 2024 owing to their wide applications in molecular diagnostic assays
  • Based on disease type, the infectious disease segment is expected to dominate the market throughout the forecast period
  • In terms of technology type, the histology assays segment held the largest share in 2024 owing to the utility of histology assays in cancer diagnostics, coupled with a rising incidence of different cancer types
  • By end use, hospital and diagnostic labs dominated the market in 2024. They witness a high inflow of biopsy specimens for histopathology and cytopathology because of an increase in hospitalization and rise in the number of hospital admissions for cancer patients
  • North America dominated the overall market in 2024 owing to the presence of a substantial number of players in this region including Innovative Research; Bio-Rad Laboratories, Inc.; Rockland Immunochemicals, Inc.; MyBioSource.com; and RayBiotech, Inc.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Enzyme
    • 1.2.2. Disease
    • 1.2.3. Technology
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Enzyme outlook
    • 2.2.2. Disease outlook
    • 2.2.3. End use outlook
    • 2.2.4. Technology outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. In-vitro Diagnostics Enzymes Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Prevalence of Chronic Diseases
      • 3.2.1.2. Advancements in Diagnostic Technologies
      • 3.2.1.3. Rising Demand for Personalized Medicine
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Diagnostic Tests
      • 3.2.2.2. Lack of Awareness in Emerging Markets
  • 3.3. In-vitro Diagnostics Enzymes Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. In-vitro Diagnostics Enzymes Market: Enzyme Estimates & Trend Analysis

  • 4.1. Enzyme Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global In-vitro Diagnostics Enzymes Market by Enzyme Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Proteases
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.2. Polymerase & Transcriptase
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Ribonuclease
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. In-vitro Diagnostics Enzymes Market: Disease Estimates & Trend Analysis

  • 5.1. Disease Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global In-vitro Diagnostics Enzymes Market by Disease Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Infectious Disease
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 5.4.1.2. COVID -19 Testing
        • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Hepatitis
        • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.4. HIV
        • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.5. Others
        • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Diabetes
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Oncology
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Cardiology
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Nephrology
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. Autoimmune Diseases
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.7. Others
      • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. In-vitro Diagnostics Enzymes Market: Technology Estimates & Trend Analysis

  • 6.1. Technology Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global In-vitro Diagnostics Enzymes Market by Technology Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Histology Assays
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Molecular Diagnostics
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.2. PCR Assays
        • 6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.3. NGS Assays
        • 6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.4. Others
        • 6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Clinical Chemistry
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. In-vitro Diagnostics Enzymes Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global In-vitro Diagnostics Enzymes Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Pharma & Biotech
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.2. Hospital & Diagnostic Labs
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Academic Labs
      • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. In-vitro Diagnostics Enzymes Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Target disease prevalence
      • 8.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Target disease prevalence
      • 8.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Target disease prevalence
      • 8.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Target disease prevalence
      • 8.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Target disease prevalence
      • 8.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Target disease prevalence
      • 8.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Target disease prevalence
      • 8.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Target disease prevalence
      • 8.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Target disease prevalence
      • 8.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Target disease prevalence
      • 8.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Target disease prevalence
      • 8.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Target disease prevalence
      • 8.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Target disease prevalence
      • 8.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. Target disease prevalence
      • 8.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Target disease prevalence
      • 8.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Target disease prevalence
      • 8.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Target disease prevalence
      • 8.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Target disease prevalence
      • 8.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
      • 8.8.1.6. )
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Target disease prevalence
      • 8.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. Target disease prevalence
      • 8.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Target disease prevalence
      • 8.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Target disease prevalence
      • 8.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Target disease prevalence
      • 8.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Key company market share analysis, 2024
    • 9.3.2. Merck KGaA
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Product benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Codexis, Inc
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. F. Hoffmann-La Roche Ltd
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Amano Enzymes Inc
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Advanced Enzymes Technologies Ltd.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Biocatalysts Ltd
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Amicogen
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Dyadic International
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. BBI Solutions
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Affymetrix
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 3 North America in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 4 North America in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 5 North America in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
  • Table 7 U.S. in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 8 U.S. in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 9 U.S. in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 10 U.S. in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 12 Canada in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 13 Canada in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 14 Canada in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 16 Mexico in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 17 Mexico in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 18 Mexico in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 20 Europe in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 21 Europe in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 22 Europe in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 23 Europe in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
  • Table 24 Germany in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 25 Germany in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 26 Germany in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 27 Germany in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 29 UK in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 30 UK in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 31 UK in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 32 France in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 33 France in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 34 France in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 35 France in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Italy in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 37 Italy in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 38 Italy in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 39 Italy in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Spain in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 41 Spain in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 42 Spain in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 43 Spain in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Sweden in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 45 Sweden in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 46 Sweden in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 47 Sweden in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Norway in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 49 Norway in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 50 Norway in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 51 Norway in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Denmark in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 53 Denmark in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 54 Denmark in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 55 Denmark in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
  • Table 61 China in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 62 China in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 63 China in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 64 China in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Japan in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 66 Japan in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 67 Japan in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 68 Japan in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 69 India in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 70 India in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 71 India in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 72 India in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 73 Australia in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 74 Australia in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 75 Australia in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 76 Australia in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Thailand in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 78 Thailand in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 79 Thailand in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 80 Thailand in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 81 South Korea in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 82 South Korea in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 83 South Korea in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 84 South Korea in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Latin America in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 86 Latin America in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 87 Latin America in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 88 Latin America in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 89 Latin America in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
  • Table 90 Brazil in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 91 Brazil in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 92 Brazil in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 93 Brazil in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 94 Argentina in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 95 Argentina in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 96 Argentina in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 97 Argentina in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 98 Middle East and Africa in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 99 Middle East and Africa in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 100 Middle East and Africa in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 101 Middle East and Africa in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 102 Middle East and Africa in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
  • Table 103 South Africa in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 104 South Africa in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 105 South Africa in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 106 South Africa in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 111 UAE in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 112 UAE in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 113 UAE in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 114 UAE in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
  • Table 115 Kuwait in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
  • Table 116 Kuwait in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
  • Table 117 Kuwait in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
  • Table 118 Kuwait in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 In-vitro diagnostics enzymes: Market outlook
  • Fig. 9 In-vitro diagnostics enzymes: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 In-vitro diagnostics enzymes market driver impact
  • Fig. 15 In-vitro diagnostics enzymes market restraint impact
  • Fig. 16 In-vitro diagnostics enzymes market strategic initiatives analysis
  • Fig. 17 In-vitro diagnostics enzymes market: Enzyme movement analysis
  • Fig. 18 In-vitro diagnostics enzymes market: Enzyme outlook and key takeaways
  • Fig. 19 Proteases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Polymerase & transcriptase market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Ribonuclease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 In-vitro diagnostics enzymes market: Disease type movement analysis
  • Fig. 24 In-vitro diagnostics enzymes market: Disease type outlook and key takeaways
  • Fig. 25 Infectious disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Cardiology market estimates and forecasts, 2018 - 2030
  • Fig. 29 Nephrology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Autoimmune diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 In-vitro diagnostics enzymes market: Technology movement analysis
  • Fig. 33 In-vitro diagnostics enzymes market: Technology outlook and key takeaways
  • Fig. 34 Histology assays market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Clinical chemistry market estimates and forecasts, 2018 - 2030
  • Fig. 37 Others market estimates and forecasts, 2018 - 2030
  • Fig. 38 In-vitro diagnostics enzymes market: End use movement analysis
  • Fig. 39 In-vitro diagnostics enzymes market: End use outlook and key takeaways
  • Fig. 40 Pharma & biotech market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Hospital & diagnostic labs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Contract Research Organizations (CROs) market estimates and forecasts, 2018 - 2030
  • Fig. 43 Academic labs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Global in-vitro diagnostics enzymes market: Regional movement analysis
  • Fig. 45 Global in-vitro diagnostics enzymes market: Regional outlook and key takeaways
  • Fig. 46 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)